YAP1 and non-small cell lung carcinoma: YAP-driven resistance to targeted therapies in non-small-cell lung cancer can be mediated, in part, by enhanced AXL expression, which has been shown to be YAP-dependent, and the inhibition of AXL kinase activity results in restored drug sensitivity [121].